HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Non-Current Debt (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Non-Current Debt came in at $72.1 million in Q2 2026, up 6.28% year-over-year from $67.8 million in Q2 2025, and up 5.74% quarter-over-quarter from $68.2 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Non-Current Debt (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Non-Current Debt for 12 consecutive years, with $72.1 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Non-Current Debt rose 6.28% year-over-year to $72.1 million in Q2 2026; TTM through Jun 2026 was $72.1 million, a 6.28% increase from a year earlier, with the FY2025 full-year figure at $68.2 million, changed N/A from the prior year.
  • Non-Current Debt was $72.1 million for Q2 2026 at HUTCHMED (China), up from $68.2 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $72.1 million in Q2 2026 and troughed at $418000.0 in Q2 2022.
  • A 5-year average of $46.1 million and a median of $55.6 million in 2024 frame the typical range for Non-Current Debt.
  • Across the five-year window, Non-Current Debt surged 9504.55% in 2023 and advanced 6.28% in 2026, its largest moves.
  • Over 5 years, Non-Current Debt stood at $18.1 million in 2022, then soared by 121.76% to $40.1 million in 2023, then surged by 38.57% to $55.6 million in 2024, then rose by 22.57% to $68.2 million in 2025, then increased by 5.74% to $72.1 million in 2026.
  • The last three Non-Current Debt figures came in at $72.1 million (Q2 2026), $68.2 million (Q4 2025), and $67.8 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Amgen 211.28 Bn 197.29 Bn 7.24 Bn 57.30 Bn
2 Gilead Sciences 181.28 Bn 178.10 Bn 6.22 Bn 26.25 Bn
3 Vertex Pharmaceuticals 132.26 Bn 124.41 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.58 Bn 74.58 Bn 3.93 Bn 1.99 Bn
5 Argenx Se 61.67 Bn 56.48 Bn 1.37 Bn -
6 Moderna 54.58 Bn 49.44 Bn 52.00 Mn 591.00 Mn
7 Alnylam Pharmaceuticals 34.01 Bn 30.70 Bn 992.69 Mn -
8 Biogen 31.26 Bn 29.98 Bn 1.96 Bn 7.29 Bn
9 Roivant Sciences 29.78 Bn 29.78 Bn 1.16 Mn -
10 HUTCHMED (China) 376.85 Mn 391.04 Mn - 72.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 72.10 Mn
Dec 31, 2025 68.19 Mn
Jun 30, 2025 67.84 Mn
Jun 30, 2024 55.63 Mn
Jun 30, 2023 40.15 Mn
Dec 31, 2022 18.10 Mn
Jun 30, 2022 418,000.00
Mar 31, 2021 26.87 Mn
Dec 31, 2020 26.86 Mn
Jun 30, 2020 26.84 Mn
Dec 31, 2019 26.82 Mn
Mar 31, 2019 26.76 Mn
Dec 31, 2018 26.74 Mn
Jun 30, 2018 26.69 Mn
Jun 30, 2017 19.99 Mn
Dec 31, 2016 26.83 Mn
Jun 30, 2016 26.80 Mn
Dec 31, 2015 26.77 Mn